Answers are grounded in this paper and cite their sources.
The prevalence of obesity has nearly tripled between 1975 and 2016 (World Health Organisation 2017). In 2016, it was estimated that 1.9 billion adults were overweight (i.e., about 40% of the of the world's adult population) of which 650 million were obese.1 Likewise, these changes were reflected in children and adolescents. Notably, more deaths are nowadays linked with overweight and obesity than underweight. Obesity is indeed a major risk factor for many nutrition-related noncommunicable diseases, including insulin resistance and diabetes mellitus, dyslipidemia, hypertension, cardiovascular diseases, and certain forms of cancer. A number of health professional organizations has recognized obesity as a chronic disease,2 such as the American Medical Association in 2013. Similarly, in the past decades, an increasing prevalence has been observed for both types 1 and 2 diabetes (T1D and T2D). Moreover, it is estimated that there are in the order of 420 million adults with diabetes worldwide (International Diabetes Federation 2015), and, at high risk of developing diabetes, 320 million adults with impaired glucose tolerance.3 The number of annual deaths caused directly by diabetes or accounted for by high blood glucose is now approaching 5 million. Encouragingly, T2D can be prevented or delayed, however, the cause of T1D has yet to be firmly established. T1D accounts for 5–10% of the cases of diabetes and there are over half a million children living with T1D. Since the sequencing of the human genome and the development of "omic" technologies, there have been a wide range of studies aimed at establishing genetic associations and biomarkers of risk toward the latter afflictions. With the collection and analysis of longitudinal samples from large human cohorts, using proteomics, transcriptomics, and metabolomics, these biobanks are anticipated to provide new insights into the Robert Moulder Domitille Schvartz David R. Goodlett Loïc Dayon etiology and the mechanisms of these diseases, with the hope of identifying further strategies for prevention and treatment. For example, the DiOGenes European project has collected samples from 350 families (distributed among eight different European countries) and followed the influence of a dietary intervention upon health status; it aimed at better understanding the dynamics and capacity to reduce/maintain weight and contributing to obesity prevention with personalized nutrition solutions. In accompaniment to traditional clinical and genomic measurements, there have been several proteomic analyses of samples collected in this study. For example, Cominetti et al. used isobaric labeling and an automated system to determine the mass spectrometry based proteomic profiles of 1000 plasma samples collected in DiOGenes.4 Similarly, Geyer et al. demonstrated the utility of their label-free approach to determine ≈350 plasma samples from 43 obese subjects in another dietary intervention study.5 Clinically orientated studies toward diabetes have ranged from the studies of the islet cell proteome, the search for new T1D autoantigens, and biomarkers defining the risk of diabetes and its related complications. The latter studies have been centered on the use of samples collected from prospective longitudinal cohorts from T1D-risk and T2D patients.6, 7 Along those lines, von Toerne et al. recently reported the identification of protein biomarker candidates associated with prediabetes in 439 plasma samples from the KORA F4 study using a targeted MS assay.7 Since its initiation in 2012, the Human Diabetes Proteome Project (HDPP) has globally combined the research strengths of several research groups to investigate the early stages of diabetes in preclinical and clinical research studies.8 Starting with an initial focus on the islets of Langerhans and insulin-producing cell lines, the HDPP studies have also included human samples from diabetes-related cohorts. Further investigations have targeted tissues in which glucose and lipids could promote protein dysfunctions, triggering diabetes initiation and progression. In this issue, three contributions were gathered showing some of the current trends in the field in terms of preclinical and clinical research using the proteomic tool box. From the study of organelles in animal models to the investigation of clinical samples, realistically achievable today in larger human cohorts, proteomics has matured as a key technology to determine biomarkers, decipher altered protein levels and biological pathways, and provide further mechanism understanding of diabetes, obesity, and related disorders. We thank all the authors for their contributions, the reviewers for their expert comments, the editors of PROTEOMICS—Clinical Applications for their continuous support, and the publishers.
No takes yet. Share an insight, caveat, or question.
Moulder et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: